Stock Details
GILD is Gilead Sciences, Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 61.35$. Average daily volumn in 3 months 9.58M. Market cap 81.54B



Stock symbol : GILD. Exchange : NasdaqGS. Currency : USD
Lastest price : 65.01$. Total volume : 7.11M. Market state PREPRE
Click reload if you want to check the lastest price on market!!!

Gilead Sciences, Inc. (GILD)
Last Price
65.01$
Change
0.66
Volume
7.11M

Previous Close64.35
Open64.45
Day Range64.01-65.19
Bid0.00 x 1.8k
Ask0.00 x 1.2k
Volume7.11M
Average Volume9.58M
Market Cap81.54B
Beta0.39
52 Week Range57.19-74.12
Trailing P/E18.16
Foward P/E10.21
Dividend (Yield %)4.54%
Ex-Dividend Date2022-06-14



Financial Details


According to Gilead Sciences, Inc.'s financial reports the company's revenue in 2021 were 27.3B an increase( +12.5%) over the years 2020 revenue that were of 24.69B. In 2021 the company's total earnings were 6.22B while total earnings in 2020 were 123M( +4778.05%).


Loading ...



Organization

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of li... ver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Market Cap:
81.54B
Revenue:
27.3B
Total Assets:
67.95B
Total Cash:
5.34B


News about "Gilead Sciences, Inc."

analysts-set-expectations-for-gilead-sciences-incs-q2-2022-earnings-nasdaqgild-image

Analysts Set Expectations for Gilead Sciences, Inc.โ€™s Q2 2022 Earnings (NASDAQ:GILD)

Source from : Defense World - 1 days ago

Research analysts at SVB Leerink issued their Q2 2022 earnings per share estimates for shares of Gilead Sciences in a research note issued to investors on Sunday, May 22nd. SVB Leerink analyst G.See details»


the-countdown-is-on-gilead-sciences-inc-gild-image

The countdown is on: Gilead Sciences Inc. (GILD)

Source from : investchronicle - 2 days ago

For the readers interested in the stock health of Gilead Sciences Inc. (GILD). It is currently valued at $63.66. When the transactions were called off in the previous session, Stock hit the highs of ...See details»


svb-leerink-weighs-in-on-gilead-sciences-incs-q2-2023-earnings-nasdaqgild-image

SVB Leerink Weighs in on Gilead Sciences, Inc.โ€™s Q2 2023 Earnings (NASDAQ:GILD)

Source from : Defense World - 2 days ago

Stock analysts at SVB Leerink issued their Q2 2023 earnings estimates for Gilead Sciences in a report released on Sunday, May 22nd. SVB Leerink analyst G. Porges forecasts that the biopharmaceutical ...See details»


why Gilead Sciences Inc. [GILD] is a Good Choice for Investors After New Price Target of $69.35

Source from : dbtnews - 1 days ago

Northampton, MA โ€“News Directโ€“ Gilead Sciences. In the winter 2019, Kavita Juneja found herself at the center of a maelstrom. A strange and deadly virus known as SARS-CoV-2 was ...See details»


gilead-at-forefront-of-herculean-effort-to-combat-covid-19-image

Gilead at Forefront of Herculean Effort to Combat COVID-19

Source from : CSR Wire - 2 days ago

Gilead scientists had planned for a moment like this through years of research. When coronaviruses with pandemic potential, like SARS and MERS, emerged in the early 2000s, Gilead began searching for ...See details»


did-gilead-sciences-inc-nasdaqgild-use-debt-to-deliver-its-roe-of-23-image

Did Gilead Sciences, Inc. (NASDAQ:GILD) Use Debt To Deliver Its ROE Of 23%?

Source from : YAHOO!News - 12 days ago

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article ...See details»


Gilead Sciences Inc. [GILD] is -14.28% lower this YTD. Is it still time to buy?

Source from : dbtnews - 8 days ago

Gilead Sciences Inc. stock went on a downward... Gilead Sciences Inc. [NASDAQ: GILD] stock went on a downward path that fall over -0.21% on Monday, amounting to a one-week price increase of more than ...See details»


gilead-reaches-number-one-spot-as-top-overall-philanthropic-funder-of-hiv-related-programs-according-to-funders-concerned-about-aids-report-image

Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report

Source from : Yahoo Finance - 1 days ago

FOSTER CITY, Calif., May 25, 2022 /3BL Media/ Gilead Sciences, Inc. (Nasdaq: GILD) was officially recognized as the number one philanthropic funder of HIV-related programs in a new tracking report ...See details»


Gilead Sciences, Inc. (NASDAQ:GILD) Forecasted to Earn Q2 2022 Earnings of $1.57 Per Share

Source from : ETF Daily News - 24 days ago

Gilead Sciences, Inc. (NASDAQ:GILD โ€“ Get Rating) โ€“ Equities researchers at Jefferies Financial Group lowered their Q2 2022 earnings per share estimates for shares of Gilead Sciences in a ...See details»


Gilead Sciences, Inc. (GILD) CEO Daniel O'Day on Q1 2022 Results - Earnings Call Transcript

Source from : Seeking Alpha - 27 days ago

Thank you for standing by and welcome to the Gilead Sciences First Quarter 2022 Earnings Conference Call. [Operator Instructions]. I will now like to hand the call over to your host for today's ...See details»


the-zacks-analyst-blog-highlights-jpmorgan-chase-gilead-sciences-csx-cvs-health-and-china-petroleum-chemical-image

The Zacks Analyst Blog Highlights JPMorgan Chase, Gilead Sciences, CSX, CVS Health and China Petroleum & Chemical

Source from : YAHOO!Finance - 3 days ago

JPMorgan Chase, Gilead Sciences, CSX, CVS Health and China Petroleum & Chemical have been included in this Analyst Blog.See details»


top-research-reports-for-jpmorgan-gilead-sciences-csx-image

Top Research Reports for JPMorgan, Gilead Sciences & CSX

Source from : YAHOO!Finance - 5 days ago

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Gilead Sciences, Inc. (GILD) and CSX Corporation (CSX).See details»


FDA Lifts Clinical Hold On Gilead's Investigational Lenacapavir For Treatment & Prevention Of HIV

Source from : Nasdaq - 9 days ago

(RTTNews) - The U.S. Food and Drug Administration has lifted the clinical hold placed on Gilead Sciences Inc.'s (GILD) Investigational New Drug Application or IND to evaluate injectable lenacapavir ...See details»


where-gilead-sciences-stands-with-analysts-image

Where Gilead Sciences Stands With Analysts

Source from : Benzinga.com - 8 days ago

Over the past 3 months, 10 analysts have published their opinion on Gilead Sciences GILD stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company ...See details»